{
    "clinical_study": {
        "@rank": "89067", 
        "acronym": "DIDo", 
        "arm_group": [
            {
                "arm_group_label": "2 icodextrin bags/day", 
                "arm_group_type": "Experimental", 
                "description": "2 icodextrin bags + 1 glucose per day"
            }, 
            {
                "arm_group_label": "1 icodextrin bag/day", 
                "arm_group_type": "Active Comparator", 
                "description": "1 icodextrin bag + 2 glucose bags per day"
            }
        ], 
        "brief_summary": {
            "textblock": "The DIDo study is an open-label, randomised, multicentre study with 2 parallel groups in\n      incident CAPD patients aged of 65 at minimum :\n\n        -  One group in which patients will receive 2 bags of icodextrin/day and 1 bag of glucose\n\n        -  One group in which patients will receive 1 bag of icodextrin/day and 2 bags of glucose."
        }, 
        "brief_title": "Efficacy and Safety of a Double Icodextrin Dose in Elderly Incident CAPD Patients on Incremental PD.", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Renal Insufficiency", 
        "condition_browse": {
            "mesh_term": "Renal Insufficiency"
        }, 
        "detailed_description": {
            "textblock": "The DiDo study evaluates efficacy and safety of a Double Icodextrin Dose in elderly incident\n      CAPD patients on incremental Peritoneal Dialysis therapy.\n\n      The objective is to demonstrate the superiority and safety of using 2, as compared to 1,\n      icodextrin bags / day, in a cohort of elderly incident continuous ambulatory peritoneal\n      dialysis (CAPD) patients using incremental peritoneal dialysis (PD) (3 bags / day), with the\n      aim of prolonging the period of time for which incremental PD can be used.\n\n      This is a phase IV open-label, randomised, multicentre study with 2 parallel groups, which\n      will take place in up to 30 hospital out-patient clinics un Europe.\n\n      It is planned to include 160 patients on the run-in period in order to obtain 100 randomised\n      patients and 90 patients evaluable at the primary endpoint (45 in each group). The duration\n      of patient recruitment is estimated at 1 year but this may be extended until all 160\n      patients are recruited.\n\n      There are 2 periods: a run-in period of 2 months and a treatment period of 18 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Run-in period\n\n          -  Incident CAPD patients who require incremental PD and in whom a 2L dialysate can be\n             safely instilled,\n\n          -  Creatinine clearance < 20 ml / min (calculated with the modification of the Diet in\n             renal Disease [MDRD] formula),\n\n          -  Age \u2265 65 years,\n\n          -  Patients willing and able to give written informed consent and comply with the\n             requirements of the study protocol.\n\n        Treatment period\n\n          -  Patients having successfully completed the run-in period (achieving euvolemia)\n\n        Exclusion Criteria:\n\n        Run-in period\n\n          -  Contraindication for CAPD according to local practice,\n\n          -  Life expectancy < 6 months,\n\n          -  Known allergy to icodextrin (cloudy dialysate or skin rash),\n\n          -  Need for amino-acid prescription,\n\n          -  Treatment with any investigational product within 30 days prior to signature of the\n             informed consent form (ICF)\n\n          -  History of drug or alcohol abuse within 3 months prior to the signature of the ICF.\n\n        Treatment period\n\n          -  Severe symptomatic arterial hypotension at the end the run-in period in the\n             Investigator's opinion,\n\n          -  Excessive ultrafiltration (UF) during the run-in period,\n\n          -  Allergy to icodextrin discovered during the run-in period,\n\n          -  Impossibility to achieve adequate PD regimen within the run-in period (catheter\n             dysfunction, peritoneal leaks, inadequate compliance, psychosocial reasons)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "65 Years"
        }, 
        "enrollment": {
            "#text": "160", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01944852", 
            "org_study_id": "UCL_2011_DIDo"
        }, 
        "intervention": {
            "arm_group_label": [
                "2 icodextrin bags/day", 
                "1 icodextrin bag/day"
            ], 
            "intervention_name": "Icodextrin", 
            "intervention_type": "Drug", 
            "other_name": "Extraneal"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "icodextrin", 
            "double dose", 
            "elderly incident CAPD patients", 
            "DIDo study"
        ], 
        "lastchanged_date": "September 13, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Brussels", 
                    "country": "Belgium", 
                    "zip": "1200"
                }, 
                "name": "Cliniques Universitaires Saint-Luc"
            }, 
            "investigator": {
                "last_name": "Eric Goffin, Professor", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_arms": "2", 
        "official_title": "Efficacy and Safety of a Double Icodextrin Dose in Elderly Incident CAPD Patients on Incremental Peritoneal Dialysis Therapy: the DIDo Study", 
        "overall_contact": {
            "email": "Eric.Goffin@uclouvain.be", 
            "last_name": "Eric Goffin, Prof", 
            "phone": "+32 2 764 18 55"
        }, 
        "overall_contact_backup": {
            "email": "taraneh.khodabandehlou@keyrus.com", 
            "last_name": "Taraneh Khodabandehlou", 
            "phone": "+33 1 41 34 12 05"
        }, 
        "overall_official": {
            "affiliation": "UCL", 
            "last_name": "Eric Goffin", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Belgium: Federal Agency for Medicinal Products and Health Products", 
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "France: Committee for the Protection of Personnes"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary endpoint will be the proportion of patients stopping 3 bags / day for the following reasons:\nUse of > 15 % hypertonic glucose dialysate 3.86 % or > 30 % hypertonic glucose dialysate 2.27 % over a 4-week period19-20,\nTransfer of the patient to another dialysis method (HD, APD, CAPD with > 3 bags / day) for any reason,\nDeath of the patient.", 
            "measure": "Proportion of patients stopping 3 bags / day", 
            "safety_issue": "No", 
            "time_frame": "Until 18 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01944852"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Universit\u00e9 Catholique de Louvain", 
            "investigator_full_name": "Pr Eric Goffin", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "\u2022\tMetabolic control: HbA1c and lipid concentration (total, high-density lipoprotein [HDL], low-density lipoprotein [LDL], triglycerides, cholesterol)", 
                "measure": "effect on clinical and biological determinants", 
                "safety_issue": "No", 
                "time_frame": "Until 18 months"
            }, 
            {
                "description": "\u2022\tBlood pressure control, evaluated by the number of anti-hypertensive agents and daily furosemide dose, and measured at the end of each study visit", 
                "measure": "effect on clinical and biological determinants", 
                "safety_issue": "No", 
                "time_frame": "Until 18 months"
            }, 
            {
                "description": "\u2022\tNutritional aspect: serum albumin and prealbumin concentrations based on the changes in percentage at various time points compared to baseline (V2)", 
                "measure": "effect on clinical and biological determinants", 
                "safety_issue": "No", 
                "time_frame": "Until 18 months"
            }, 
            {
                "description": "\u2022\tInflammatory profile: CRP concentrations", 
                "measure": "effect on clinical and biological determinants", 
                "safety_issue": "No", 
                "time_frame": "Until 18 months"
            }, 
            {
                "description": "\u2022\tLeft ventricular mass calculated following echocardiography", 
                "measure": "effect on clinical and biological determinants", 
                "safety_issue": "No", 
                "time_frame": "Until 18 months"
            }, 
            {
                "description": "\u2022\tQuality of life according to KDQoL", 
                "measure": "effect on clinical and biological determinants", 
                "safety_issue": "No", 
                "time_frame": "Until 18 months"
            }, 
            {
                "description": "\u2022\tResidual renal function evaluated by calculated GFR", 
                "measure": "effect on clinical and biological determinants", 
                "safety_issue": "No", 
                "time_frame": "Until 18 months"
            }, 
            {
                "description": "\u2022\tPeritoneal membrane permeability assessed by the PET", 
                "measure": "effect on clinical and biological determinants", 
                "safety_issue": "No", 
                "time_frame": "Until 18 months"
            }, 
            {
                "description": "\u2022\tNumber of hospitalisations and length (in days) of hospitalisation", 
                "measure": "effect on clinical and biological determinants", 
                "safety_issue": "No", 
                "time_frame": "Until 18 months"
            }, 
            {
                "description": "\u2022\tAdverse events (AEs), treatment-emergent AEs and serious adverse events (SAEs)", 
                "measure": "Safety endpoints", 
                "safety_issue": "Yes", 
                "time_frame": "Until 18 months"
            }, 
            {
                "description": "\u2022\tSerum sodium concentration and icodextrin metabolites concentration", 
                "measure": "6.1.3 Safety endpoints", 
                "safety_issue": "Yes", 
                "time_frame": "Until 18 months"
            }, 
            {
                "description": "\u2022\tRelevant clinical problems related to serum sodium concentration and to icodextrin metabolites accumulation", 
                "measure": "safety endpoints", 
                "safety_issue": "Yes", 
                "time_frame": "Until 18 months"
            }, 
            {
                "description": "\u2022\tIncidence of skin rashes", 
                "measure": "Safety endpoints", 
                "safety_issue": "Yes", 
                "time_frame": "Until 18 months"
            }, 
            {
                "description": "\u2022\tIncidence of sterile peritonitis", 
                "measure": "Safety endpoints", 
                "safety_issue": "Yes", 
                "time_frame": "Until 18 months"
            }
        ], 
        "source": "Universit\u00e9 Catholique de Louvain", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pr Eric Goffin", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}